Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | TYMS | P04818 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.30 |
| ▸ | CASP1 | P29466 | 1/20 | 0.30 |
| ▸ | CASP7 | P55210 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL78889 | 0.76 | TDP1 (0.41) | KDM4ETYMSALDH1A1TP53CYP3A4 | |
| SCHEMBL78155 | 0.72 | ACHE (0.35) | KDM4ETYMSSIRT2 | |
| SCHEMBL23932622 | 0.72 | KDM4E (0.48) | KDM4EALDH1A1TP53CYP3A4TSHR | |
| SCHEMBL4017362 | 0.70 | KDM4E (0.34) | KDM4EALDH1A1TP53CYP3A4TSHR | |
| SCHEMBL79135 | 0.68 | BRD4 (0.43) | KDM4ETYMSALDH1A1CYP3A4TDP1 | |
| SCHEMBL78707 | 0.67 | MAPK14 (0.36) | KDM4EALDH1A1CASP1CASP7HSD17B10 | |
| SCHEMBL77529 | 0.67 | ALDH1A1 (0.37) | TYMSALDH1A1HSD17B10 | |
| SCHEMBL1508681 | 0.66 | TYMS (0.46) | KDM4ETYMSALDH1A1SIRT2HSD17B10 | |
| SCHEMBL30832653 | 0.66 | TYMS (0.46) | KDM4ETYMSALDH1A1SIRT2HSD17B10 | |
| SCHEMBL27907963 | 0.65 | ALDH1A1 (0.46) | KDM4EALDH1A1TP53CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7531608-B2 | Transition metal complexes, catalyst compositions containing the same, and olefin polymerization using the catalyst compositions | LG CHEM, LTD. (KR) | 2009-05-12 | — | — | US | disclosed |
| WO-2007007991-A1 | TRANSITION METAL COMPLEXES, CATALYST COMPOSITIONS CONTAINING THE SAME, OLEFIN POLYMERIZATION USING THE CATALYST COMPOSITIONS | LG CHEM, LTD. (KR) | 2007-01-18 | — | — | WO | disclosed |
| US-20070010638-A1 | Transition metal complexes, catalyst compositions containing the same, and olefin polymerization using the catalyst compositions | LG CHEM, LTD. (KR) | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010638-A1 | Transition metal complexes, catalyst compositions containing the same, and olefin polymerization using the catalyst compositions | CPNE4, AOC2, ODC1 | KDM4E 2895/4885TYMS 1588/4885ALDH1A1 4020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.